BERKELEY, CA (UroToday.com) - AT1 receptor blockers (ARBs) possessing our experimental demonstrations may offer clinical efficacy in patients with hormone refractory prostate cancer (HRPC).

In practice, we conducted a pilot clinical study to examine whether an ARB (candesartan) was able to clinically elicit an antiproliferative effect on hormone-refractory prostate cancer. Surprisingly, a quarter of patients with a PSA decline of more than 50% showed an improvement in performance status.

We experienced some cases in which the PSA response was delayed for several months after starting ARB treatment. Thus, we presume that the administered dose of candesartan was too low to overcome multiple metastases.

Finally, we believe that ARBs have the potential to delay the PSA increase in cases whose cancer tissues possess AT1 receptors.

Written by
Hiroji Uemura MD, PHD, as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.

Pharmacology and New Perspectives of Angiotensin II Receptor Blocker in Prostate Cancer Treatment - Abstract

read other Beyond The Abstract submissions

More Information about Beyond the Abstract

Please log-in or register in order to submit comments.

Powered by AkoComment!